60 |
Thriemer K., Degaga T.S., Alam M.S., Adhikari B., Tripura R., Hossain M.S., Christian M., Ghanchi N.K., Mnjala H., Weston S., Ley B., Rumaseb A., Tadesse D., Teferi T., Yilma D., Lee G., Unger H., Sutanto I., Pasaribu A.P., Ghimire P., Beg M.A., Price R.N. |
Adapting international clinical trials during COVID-19 and beyond |
Clinical Trials |
|
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan; Arba Minch General Hospital, Arba Minch, Ethiopia; Jimma University, Jimma, Ethiopia; Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Child Health, Universitas Sumatera Utara, Medan, Indonesia; Central Department of Microbiology, Tribhuvan University, Kirtipur, Nepal |
04079621, NCT 03916003; Bill and Melinda Gates Foundation, BMGF: OPP1164105/INV-010504; Australian Government; National Health and Medical Research Council, NHMRC: APP1182950, APP2000780, GNT1132975, INV-024389, NCT 04411836, NCT 05426434; Australian Academy of Science; Department of Industry, Innovation and Science, Australian Government |
Q1 |
|
|